This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global RNAi therapeutics market is expected to record a value of US$1.26 billion in 2027, progressing at a CAGR of 10.02%, over the period 2023-2027. Factors such as rising utilization in oncology pharmaceuticals, accelerating growth rates of infectious diseases, enlarging geriatric population, increasing prevalence of neurodegenerative disorders and progress in collaborations and associated deals in RNAi therapeutics. However, the market growth would be challenged by complexity associated with the drug delivery of RNAi therapeutics, high development cost of RNA interference-based therapeutics and stringent regulatory requirements. A few notable trends include growing popularity of personalized medicine, surging preference RNAi therapeutics as an alternative for HTS & keloids treatment and escalating applications in molecular diagnostics.
The global market has been segmented on the basis of molecule type, application and end-user. On the basis of molecule type, the global market can be bifurcated into small interfering RNAs (siRNAs) and microRNAs (miRNAs). According to applications, the market can be divided into oncology, respiratory disorders, neurological disorders, liver disorders, autoimmune disorders and other disorders. Whereas, the global RNAi therapeutics market is split into research & academic laboratories and hospitals & diagnostic laboratories, in terms of end-user.
The fastest growing regional market is North America owing to increasing prevalence of chronic conditions, rising investments for development of RNAi therapeutics along with growing number of research activities for RNA-based therapeutics in the region. Further, the COVID-19 pandemic has positively impacted the market due to the growing relevance of RNA-based investigations as well as increasing funding for R&D activities.
Scope of the report
- The report provides a comprehensive analysis of the global RNAi therapeutics market segmented on the basis of molecule type, application, end-user and region, with potential impact of COVID-19.
- The major regional and country markets (North America, Europe, Asia Pacific and RoW) have been analyzed.
- The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
- The competitive landscape of the market, along with the company profiles of leading players (Sanofi S.A., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Benitec Biopharma Ltd., and Sirnaomics, Ltd.) are also presented in detail.
Key Target Audience
- RNAi Therapeutics Service/Equipment Providers and Distributors
- Pharmaceutical, Biopharmaceutical & Biotechnological Companies
- Research and Development (R&D) Organizations
- End Users
- Government Bodies & Regulating Authorities
Please note: 10% free customization equates to up to 3 hours of analyst time.
Table of Contents
1. Market Overview
1.1 Introduction
1.2 Different Classes of RNA Therapeutics
1.3 Major Pathways of RNAi
1.4 Various Small RNA Isoforms related to RNAi
1.5 Key Features of RNAi Therapeutics
1.6 Comparison of RNAi Treatments against Other Treatment Classes
1.7 Platform Comparison of RNAi Therapeutics
1.8 Applications of RNAi in Vivo
2. Impact of COVID-19
2.1 Rapid Spread of Coronavirus
2.2 Growth in COVID-19 R&D Funding
2.3 RNA Vaccine Development for COVID-19
3. Global Market Analysis
3.1 Global RNAi Therapeutics Market by Value
3.2 Global RNAi Therapeutics Market Forecast by Value
3.3 Global RNAi Therapeutics Market by Molecule Type
3.3.1 Global Small Interfering RNA (siRNA) Therapeutics Market by Value
3.3.2 Global Small Interfering RNA (siRNA) Therapeutics Market Forecast by Value
3.3.3 Global Small Interfering RNA (siRNA) Therapeutics Market by Type
3.3.4 Global Small Interfering RNA (siRNA) Therapeutics Type Market by Value
3.3.5 Global Small Interfering RNA (siRNA) Therapeutics Type Market Forecast by Value
3.3.6 Global MicroRNA (miRNA) Therapeutics Market by Value
3.3.7 Global MicroRNA (miRNA) Therapeutics Market Forecast by Value
3.4 Global RNAi Therapeutics Market by Application
3.4.1 Global RNAi Therapeutics Application Market by Value
3.4.2 Global RNAi Therapeutics Product Market Forecast by Value
3.5 Global RNAi Therapeutics Market by End-Users
3.5.1 Global RNAi Therapeutics End-User Market by Value
3.5.2 Global RNAi Therapeutics End-User Market Forecast by Value
3.6 Global RNAi Therapeutics Market by Region
4. Regional Market Analysis
4.1 North America
4.1.1 North America RNAi Therapeutics Market by Value
4.1.2 North America RNAi Therapeutics Market Forecast by Value
4.1.3 The U.S. RNAi Therapeutics Market Forecast by Value
4.2 Europe
4.2.1 Europe RNAi Therapeutics Market by Value
4.2.2 Europe RNAi Therapeutics Market Forecast by Value
4.3 Asia Pacific
4.3.1 Asia Pacific RNAi Therapeutics Market by Value
4.3.2 Asia Pacific RNAi Therapeutics Market Forecast by Value
4.4 RoW
4.4.1 RoW RNAi Therapeutics Market by Value
4.4.2 RoW RNAi Therapeutics Market Forecast by Value
5. Market Dynamics
5.1 Growth Drivers
5.1.1 Rising Utilization in Oncology Pharmaceuticals
5.1.2 Accelerating Growth Rates of Infectious Diseases
5.1.3 Enlarging Geriatric Population
5.1.4 Increasing Prevalence of Neurodegenerative Disorders
5.1.5 Progress in Collaborations & Associated Deals in RNAi Therapeutics
5.1.6 Expanding Research & Development Activities
5.2 Key Trends and Developments
5.2.1 Growing Popularity of Personalized Medicine
5.2.2 Surging Preference as an Alternative for HTS & Keloids Treatment
5.2.3 Escalating Applications in Molecular Diagnostics
5.2.4 Development of RNAi Therapeutics
5.3 Challenges
5.3.1 Complexity Associated with the Delivery of RNAi Therapeutics
5.3.2 High Development Cost of RNA Interference-Based Therapeutics
5.3.3 Stringent Regulatory Requirements
6. Company Profiles
6.1 Sanofi S.A. (Genzyme Corporation)
6.1.1 Business Overview
6.2 Alnylam Pharmaceuticals Inc.
6.2.1 Business Overview
6.3 Arrowhead Pharmaceuticals Inc.
6.3.1 Business Overview
6.4 Arbutus Biopharma Corporation
6.4.1 Business Overview
6.5 Benitec Biopharma Ltd.
6.5.1 Business Overview
6.6 Sirnaomics, Ltd.
6.6.1 Business Overview
List of Charts
- Schematic Illustration of Different Classes of RNA Therapeutics
- RNA Interference Therapeutic Process
- Various Small RNA Isoforms related to RNAi
- Key Features of RNAi Therapeutics
- Applications of RNAi in Vivo
- Number of Cumulative Cases of Coronavirus (COVID-19) Worldwide (2020)
- Global RNAi Therapeutics Market by Value (2018-2022)
- Global RNAi Therapeutics Market Forecast by Value (2023-2027)
- Global RNAi Therapeutics Market by Molecule Type (2022)
- Global Small Interfering RNA (siRNA) Therapeutics Market by Value (2018-2022)
- Global Small Interfering RNA (siRNA) Therapeutics Market Forecast by Value (2023-2027)
- Global Small Interfering RNA (siRNA) Therapeutics Market by Type (2022)
- Global Small Interfering RNA (siRNA) Therapeutics Type Market by Value (2018-2022)
- Global Small Interfering RNA (siRNA) Therapeutics Type Market Forecast by Value (2023-2027)
- Global MicroRNA (miRNA) Therapeutics Market by Value (2018-2022)
- Global MicroRNA (miRNA) Therapeutics Market Forecast by Value (2023-2027)
- Global RNAi Therapeutics Market by Application (2022)
- Global RNAi Therapeutics Application Market by Value (2018-2022)
- Global RNAi Therapeutics Product Market Forecast by Value (2023-2027)
- Global RNAi Therapeutics Market by End-Users (2022)
- Global RNAi Therapeutics End-User Market by Value (2018-2022)
- Global RNAi Therapeutics End-User Market Forecast by Value (2023-2027)
- Global RNAi Therapeutics Market by Region (2022)
- North America RNAi Therapeutics Market by Value (2018-2022)
- North America RNAi Therapeutics Market Forecast by Value (2023-2027)
- The U.S. RNAi Therapeutics Market Forecast by Value (2020-2027)
- Europe RNAi Therapeutics Market by Value (2018-2022)
- Europe RNAi Therapeutics Market Forecast by Value (2023-2027)
- Asia Pacific RNAi Therapeutics Market by Value (2018-2022)
- Asia Pacific RNAi Therapeutics Market Forecast by Value (2023-2027)
- RoW RNAi Therapeutics Market by Value (2018-2022)
- RoW RNAi Therapeutics Market Forecast by Value (2023-2027)
- Oncology Pharmaceuticals Market in the U.S. and China (2020-2030)
- Global Growth Rate of Infectious Diseases Forecast (2017-2023)
- Global Population 65 Years and Above (2017-2022)
- Worldwide Projections of Alzheimer’s Disease Prevalence (2015-2040)
- Global Personalized Medicine Market (2018-2022)
- Market Size of Hypertrophic Scars (HTS) & Keloids Treatments (2020-2030)
- Global Molecular Diagnostics Market (2021-2026)
List of Tables
- Comparison of RNAi Treatments against Other Treatment Classes
- Platform Comparison of RNAi Therapeutics
- COVID-19 R&D Funding by Major Countries (2020)
- mRNA Vaccine in Development for COVID-19
- Deals in RNAi Therapeutics (2019-2022)
- Approved RNAi Therapeutics (2018-2022)
Companies Mentioned
- Sanofi S.A(Genzyme Corporation)
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Arbutus Biopharma Corporation
- Benitec Biopharma Ltd.
- Sirnaomics, Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 76 |
| Published | March 2023 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value ( USD | $ 0.86 Billion |
| Forecasted Market Value ( USD | $ 1.26 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 6 |
